Screener
NewAmsterdam Pharma Company NAMS Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from NewAmsterdam Pharma Company’s reported figures.
Based on the most recent quarter.
The source filing: NewAmsterdam Pharma Company’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 7:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333824
FAQ
- What is NewAmsterdam Pharma Company's debt-to-equity?
- NewAmsterdam Pharma Company (NAMS) reported debt-to-equity of 0× in Q2 2026.
- How has NewAmsterdam Pharma Company's debt-to-equity changed year-over-year?
- NewAmsterdam Pharma Company's debt-to-equity decreased by 75.0% year-over-year, from 0× to 0×.
- What is the long-term trend for NewAmsterdam Pharma Company's debt-to-equity?
- Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's debt-to-equity has grown at a 0.0% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about NewAmsterdam Pharma Company's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude